CTRI/2021/01/030802
Not yet recruiting
未知
Sacubitril/valsartan in heart failure with reduced ejection fraction (HFrEF) patients: a real-world study in India
ovartis Healthcare Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ovartis Healthcare Private Limited
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \>\= 18 years with a diagnosis of HFrEF as mentioned in database or heart failure with a recording of LVEF \<40% at or before the index date.
- •A prescription of sacubitril/valsartan
Exclusion Criteria
- •Diagnosis of HF specified as preserved/mid\-range ejection fraction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
PRAISE-MR trialHeart failure with preserved ejection fraction Secundary mitral valve regurgitationTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2023-506634-70-00Ziekenhuis Oost Limburg110
Recruiting
Not Applicable
Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection FractionHeart Failure, SystolicNCT04803175Samsung Medical Center100
Recruiting
Phase 3
The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction.2024-518239-12-00Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla II666
Completed
Phase 4
Efficacy of Sacubitril valsartan for chronic heart failure: A prospective observation studychronic heart failure during ACE-i or ARB treatmentJPRN-UMIN000041650Sekino Hospital120
Active, not recruiting
Phase 4
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve RegurgitationNCT05991284Ziekenhuis Oost-Limburg84